Neuroleptic Malignant Syndrome Due to Risperidone Treatment in a Child With Joubert Syndrome

Vurucu, Sebahattin; Cöngöloğlu, Ayhan; Altun, Demet; Ünay, Bülent; Akin, Rıdvan

doi:10.1016/s0027-9684(15)30858-0

Cited by 6 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7 As far as we know in the literature only two NMS cases due to risperidone treatment were reported in children. 8,9 We think that atypical neuroleptics will be extensively used in children in the future and the clinicians especially the pediatricians must be familiar to NMS and its differential diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Neuroleptic Malignant Syndrome Due to Risperidone Misdiagnosed as Status Epilepticus

et al. 2011

View full text Add to dashboard Cite

Neuroleptic malignant syndrome (NMS) is a rare but potentially fatal disease characterized by fever, muscle rigidity, delirium and autonomic instability. Here we report a child, with NMS due to the risperidone misdiagnosed as status epilepticus. Nine year old boy, who had been under high dose risperidone treatment for 8 weeks, admitted to the emergency room because of the contractions (evaluated as status epilepticus) persisting for 7 hours. Since there was neuroleptic treatment in the past medical history and, unconsciousness, muscular rigidity, diaphoresis, hypertermi and, hypotension in physical examination, leucocytosis and elevated creatininphosphokinase levels in laboratory tests, the patient was evaluated as NMS and discharged without any complications. We reported this case to point out that; NMS may be misdiagnosed as status epilepticus in children when EEG monitoring is unavailable. When a child admitted to the emergency room because of suspicious convulsion neuroleptic drug use must surely be asked.

show abstract

Section: Discussionmentioning

confidence: 99%

Neuroleptic Malignant Syndrome Due to Risperidone Misdiagnosed as Status Epilepticus

et al. 2011

View full text Add to dashboard Cite

show abstract

“…La incidencia reportada del SNM ha variado durante las últimas décadas, no obstante, siempre se ha caracterizado por su baja frecuencia. En 1993 se describió una incidencia del 0,2 al 3% (3) , pero en los últimos años se ha observado una disminución hasta el 0,01 al 0,02% (4) , posiblemente debido a un mayor cuidado en la prescripción y titulación de la medicación.…”

Section: Epidemiologíaunclassified

Síndrome neuroléptico maligno

Huarcaya-Victoria

2023

An Fac med

View full text Add to dashboard Cite

El síndrome neuroléptico maligno (SNM) es una reacción adversa medicamentosa potencialmente fatal asociada comúnmente a medicamentos antipsicóticos. Este artículo presenta una revisión actualizada sobre el SNM, aborda su epidemiología, factores de riesgo, presentación clínica, posibles mecanismos subyacentes y tratamiento. Se busca mejorar el reconocimiento temprano, diagnóstico y manejo del SNM en el ámbito clínico para reducir su morbimortalidad. La búsqueda de literatura se realizó en PubMed, fueron priorizados ensayos aleatorizados, revisiones sistemáticas, estudios retrospectivos y reportes de caso. La incidencia del SNM ha disminuido en los últimos años, posiblemente debido a una mejor prescripción y titulación de la medicación. Los factores de riesgo incluyen el uso de antipsicóticos de alta potencia, dosis elevadas, incremento rápido de la dosis y uso de antipsicóticos inyectables de depósito. Se han identificado factores ambientales como la deshidratación, sujeción mecánica y temperaturas extremas. Algunas características psicopatológicas, como la agitación psicomotriz y la confusión, también se han asociado al SNM. Los factores hereditarios y los polimorfismos genéticos pueden influir en la susceptibilidad al SNM, pero se requieren estudios adicionales. La fisiopatología del SNM se relaciona con el bloqueo excesivo de los receptores dopaminérgicos, pero otros cofactores y sistemas neurotransmisores también podrían estar involucrados. El cuadro clínico del SNM se caracteriza por cambios en el estado mental, rigidez muscular, hipertermia, síntomas catatónicos y sudoración profusa. Existen diversas formas de tratamiento, desde medidas generales hasta intervenciones farmacológicas.

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2009

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Neuroleptic Malignant Syndrome Due to Risperidone Treatment in a Child With Joubert Syndrome

Cited by 6 publications

References 10 publications

Neuroleptic Malignant Syndrome Due to Risperidone Misdiagnosed as Status Epilepticus

Neuroleptic Malignant Syndrome Due to Risperidone Misdiagnosed as Status Epilepticus

Síndrome neuroléptico maligno

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About